[go: up one dir, main page]

AU4391196A - A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)-isoxazole or one of its pharmaceutically acceptable salts - Google Patents

A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)-isoxazole or one of its pharmaceutically acceptable salts

Info

Publication number
AU4391196A
AU4391196A AU43911/96A AU4391196A AU4391196A AU 4391196 A AU4391196 A AU 4391196A AU 43911/96 A AU43911/96 A AU 43911/96A AU 4391196 A AU4391196 A AU 4391196A AU 4391196 A AU4391196 A AU 4391196A
Authority
AU
Australia
Prior art keywords
methyl
isoxazole
pyrrolidinyl
administration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU43911/96A
Other versions
AU719171B2 (en
Inventor
Stephen Peter Arneric
John Burns Cannon
Hanshermann Franke
Gerd Hoffmann
Heinrich Kindel
James Patrick Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority claimed from PCT/EP1996/000074 external-priority patent/WO1996021434A1/en
Publication of AU4391196A publication Critical patent/AU4391196A/en
Application granted granted Critical
Publication of AU719171B2 publication Critical patent/AU719171B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU43911/96A 1995-01-14 1996-01-10 A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)-isoxazole or one of its pharmaceutically acceptable salts Ceased AU719171B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE9501022 1995-01-14
DE9501022 1995-01-14
PCT/EP1996/000074 WO1996021434A1 (en) 1995-01-14 1996-01-10 Transdermal therapeutic system for dispensing (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazole or one of its pharmaceutically acceptable salts

Publications (2)

Publication Number Publication Date
AU4391196A true AU4391196A (en) 1996-07-31
AU719171B2 AU719171B2 (en) 2000-05-04

Family

ID=6918215

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43911/96A Ceased AU719171B2 (en) 1995-01-14 1996-01-10 A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)-isoxazole or one of its pharmaceutically acceptable salts

Country Status (1)

Country Link
AU (1) AU719171B2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313928C2 (en) * 1993-04-28 1996-09-19 Lohmann Therapie Syst Lts Transdermal therapeutic system for the controlled delivery of pilocarpine to the skin, process for its production and its use
DE4336557C2 (en) * 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiol-containing transdermal therapeutic system, process for its preparation and its use
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device

Also Published As

Publication number Publication date
AU719171B2 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
AU5945296A (en) Medicament for nasal administration
AU4449789A (en) Delivery system for pharmaceutical or therapeutic actives
ZA962536B (en) Pharmaceutical composition for transdermal administration.
AU2827095A (en) Controlled release oral drug delivery system
AU6491196A (en) Epidural administration of therapeutic compounds with sustained rate of release
AU4809596A (en) Nanosuspensions for intravenous administration
AU6534894A (en) Drug administration system
AU6558296A (en) Buccal delivery system for therapeutic agents
AU5397996A (en) Iontophoretic transdermal system for the administration of at least two substances
AU5263496A (en) Targeted catheter drug administration
AU650484B2 (en) Isoxazole compound, pharmaceutically acceptable salt thereof, and medicinal use thereof
PL314732A1 (en) S(+)-ethodolac preparations for oral administration
AU2939897A (en) Administration of histamine for therapeutic purposes
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
HUP9801130A3 (en) Transdermal therapeutic system for administering testosterone
CA2190837A1 (en) Transdermal delivery of anti-epileptic drugs
IL116912A0 (en) Novel pharmaceutical combination for topical administration
AU3107089A (en) Controlled release system for orally administered active substances
IL117809A0 (en) Medical patch for rate-controlled transdermal administration of risperidone
ZA96260B (en) A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazole or one of its pharmaceutically acceptable salts
AU6821196A (en) Transdermal administration of vorozole
AU5347996A (en) Preparation for oral administration
WO1999056734A3 (en) Transdermal therapeutic system for the administration of candesartan
AU4391196A (en) A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)-isoxazole or one of its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired